X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs LUPIN LTD - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD LUPIN LTD ALEMBIC LTD/
LUPIN LTD
 
P/E (TTM) x 55.9 28.3 197.9% View Chart
P/BV x 2.3 3.0 79.0% View Chart
Dividend Yield % 0.4 0.6 77.7%  

Financials

 ALEMBIC LTD   LUPIN LTD
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
LUPIN LTD
Mar-18
ALEMBIC LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs721,465 4.9%   
Low Rs34727 4.7%   
Sales per share (Unadj.) Rs4.7349.6 1.3%  
Earnings per share (Unadj.) Rs6.15.6 109.8%  
Cash flow per share (Unadj.) Rs6.229.6 21.1%  
Dividends per share (Unadj.) Rs0.205.00 4.0%  
Dividend yield (eoy) %0.40.5 82.8%  
Book value per share (Unadj.) Rs40.7300.3 13.5%  
Shares outstanding (eoy) m267.03452.08 59.1%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x11.33.1 359.3%   
Avg P/E ratio x8.7197.2 4.4%  
P/CF ratio (eoy) x8.537.1 22.9%  
Price / Book Value ratio x1.33.6 35.7%  
Dividend payout %3.390.0 3.6%   
Avg Mkt Cap Rs m14,139495,502 2.9%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m20728,647 0.7%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m1,255158,042 0.8%  
Other income Rs m3701,504 24.6%   
Total revenues Rs m1,625159,545 1.0%   
Gross profit Rs m11131,475 0.4%  
Depreciation Rs m3810,859 0.3%   
Interest Rs m22,044 0.1%   
Profit before tax Rs m44220,076 2.2%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m1,21235 3,443.2%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m242,885 0.8%   
Profit after tax Rs m1,6302,513 64.9%  
Gross profit margin %8.919.9 44.4%  
Effective tax rate %5.414.4 37.7%   
Net profit margin %129.81.6 8,167.4%  
BALANCE SHEET DATA
Current assets Rs m1,867122,095 1.5%   
Current liabilities Rs m59150,956 1.2%   
Net working cap to sales %101.645.0 225.8%  
Current ratio x3.22.4 131.8%  
Inventory Days Days9485 111.4%  
Debtors Days Days74120 61.3%  
Net fixed assets Rs m1,791129,876 1.4%   
Share capital Rs m534904 59.1%   
"Free" reserves Rs m10,324134,866 7.7%   
Net worth Rs m10,858135,771 8.0%   
Long term debt Rs m4164,245 0.1%   
Total assets Rs m11,591263,054 4.4%  
Interest coverage x260.910.8 2,410.1%   
Debt to equity ratio x00.5 0.8%  
Sales to assets ratio x0.10.6 18.0%   
Return on assets %14.11.7 812.7%  
Return on equity %15.01.9 811.1%  
Return on capital %15.23.7 408.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1953,141 0.0%   
Fx outflow Rs m26419,335 1.4%   
Net fx Rs m-24433,807 -0.7%   
CASH FLOW
From Operations Rs m23617,512 1.3%  
From Investments Rs m-224-14,073 1.6%  
From Financial Activity Rs m-27-14,921 0.2%  
Net Cashflow Rs m-15-11,482 0.1%  

Share Holding

Indian Promoters % 64.0 46.6 137.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.2 11.3 1.8%  
FIIs % 9.7 31.9 30.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.1 258.4%  
Shareholders   54,701 98,259 55.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - VENUS REMEDIES COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS